1. Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection
- Author
-
Martin J. Pearse, Stephen J. Kent, Shirley Taylor, Kirsten Vandenberg, Sue Lowther, Steven Rockman, Deborah Middleton, Sylvia Miescher, Darryl Maher, Sarina Camuglia, and Lou Fabri
- Subjects
IVIg ,Serum ,0301 basic medicine ,lcsh:Medicine ,NI, neuraminidase inhibition ,Antibodies, Viral ,Virus Replication ,medicine.disease_cause ,Plasma ,Influenza A Virus, H1N1 Subtype ,ARRIVE, Animal Research: Reporting of In Vivo Experiments ,hemic and lymphatic diseases ,Pandemic ,Influenza A virus ,IL, Interleukin ,Lung ,lcsh:R5-920 ,biology ,Immunoglobulins, Intravenous ,virus diseases ,Respiratory infection ,General Medicine ,Viral Load ,IFN, Interferon ,CSIRO, Commonwealth Scientific and Industrial Research Organization ,Cytokines ,Antibody ,lcsh:Medicine (General) ,Viral load ,Research Paper ,WHO, World Health Organization ,General Biochemistry, Genetics and Molecular Biology ,Virus ,HI, haemagglutination inhibition ,Passive immunotherapy ,03 medical and health sciences ,Orthomyxoviridae Infections ,IVIg, intravenous immunoglobulin ,medicine ,Animals ,Humans ,RNA, Messenger ,PBMC, Perpheral Blood Mononuclear Cells ,Pandemics ,Intravenous immunoglobulin ,Influenza A Virus, H5N1 Subtype ,business.industry ,lcsh:R ,Ferrets ,HPAI, highly pathogenic avian influenza ,CSL, Commonwealth Serum Laboratories ,RT-PCR, Reverse Transcriptase PCR ,Virology ,Influenza ,Influenza A virus subtype H5N1 ,030104 developmental biology ,PBS, Phophate Buffered Saline ,Immunology ,biology.protein ,TNF, Tumor Necrosis Factor ,business ,Neuraminidase - Abstract
Influenza is a highly contagious, acute, febrile respiratory infection that can have fatal consequences particularly in individuals with chronic illnesses. Sporadic reports suggest that intravenous immunoglobulin (IVIg) may be efficacious in the influenza setting. We investigated the potential of human IVIg to ameliorate influenza infection in ferrets exposed to either the pandemic H1N1/09 virus (pH1N1) or highly pathogenic avian influenza (H5N1). IVIg administered at the time of influenza virus exposure led to a significant reduction in lung viral load following pH1N1 challenge. In the lethal H5N1 model, the majority of animals given IVIg survived challenge in a dose dependent manner. Protection was also afforded by purified F(ab′)2 but not Fc fragments derived from IVIg, supporting a specific antibody-mediated mechanism of protection. We conclude that pre-pandemic IVIg can modulate serious influenza infection-associated mortality and morbidity. IVIg could be useful prophylactically in the event of a pandemic to protect vulnerable population groups and in the critical care setting as a first stage intervention., Highlights • Intravenous immunoglobulin (IVIg), prepared prior to a pandemic, prevents pandemic influenza disease in ferrets. • IVIg effectively reduced viral levels of pandemic H1N1 influenza and prevented disease due to avian influenza H5N1. • This work has implications for preventing and treating pandemic influenza infections with IVIg before a vaccine is available. Influenza pandemics cause large numbers of infections and deaths. There is a lag between the identification of a pandemic and the development of vaccines. Future pandemics may be caused by influenza strains resistant to current anti-influenza drugs. New treatments are needed for future pandemic influenza outbreaks. We show that a readily available product (intravenous immunoglobuling – pooled antibodies from human donors) can prevent viral replication and disease caused by 2 strains of pandemic influenza viruses (“swine-flu” and “bird-flu”) in an appropriate animal model of influenza. This could form the basis of future treatments for severe influenza caused by pandemic strains.
- Published
- 2017